

# Paravalvular Leak: Severity Assessment and Treatment

Laborde JC , MD  
St.George's hospital, London , UK

**TAVI Summit 2013, Seoul, August 8th**

# Potential conflicts of interest

**Speaker's name: Jean-claude Laborde**



I have the following potential conflicts of interest to report:

Research contracts



Consulting

Medtronic

Employment in industry

Stockholder of a healthcare company

Owner of a healthcare company

Other(s)

I do not have any potential conflict of interest

# Paravalvular Leak: Severity Assessment and Treatment


## Background

Paravalvular aortic regurgitation (PAR) negatively impacts the prognosis following transcatheter aortic valve replacement (TAVR) with dramatically increased morbidity and mortality in patients suffering from more-than-mild PAR

# Paravalvular Leak: Severity Assessment and Treatment

# Paravalvular Leak


## **predictors of early and late mortality after TAVI**



# Angiogram



T.E.E.



# Hemodynamics

# Paravalvular Leak: Severity Assessment and Treatment

## Paravalvular Leak

### Valve position and PVL assessment



- Frame Alignment
- RAO projection

- Location of Pigtail Catheter
- Amount of Contrast Medium
- Heart rate
- Pressure Level
- Projection : RAO vs LAO
- Location of Paravalvular Leak
- LV Hypertrophy / LV impaired function
- Etc.....

# How to manage significant residual aortic regurgitation

When to apply correctives mesures ?

At the time of Valve Implantation procedure

*Minimize PAR*


At Follow-up

*Symptomatique PAR*

*Increased ( or under-evaluated) PAR*

# How to manage significant residual aortic regurgitation

When to apply correctives mesures ?




# How to manage significant residual aortic regurgitation

Identify patients at risk ?

Previous patient anatomy



NO



YES

# How to manage significant residual aortic regurgitation

Identify patients at risk ?

Previous patient hemodynamic status

AS + AR Grade > III

Low flow- Low gradient  
LV Diastolic dysfunction  
Poor EF  
Severe LV Hypertrophy



NO



YES

# How to manage significant residual aortic regurgitation

Identification of the mechanism of PAR ?

✓ **stent frame underexpansion**

due to heavily calcified cusps

✓ **suboptimal placement of the prosthesis**

✓ **annulus-prosthesis-size mismatch**

due to malsizing

# How to manage significant residual aortic regurgitation

## Identification of the mechanism of PAR ?



✓ stent frame underexpansion

*nominal << effective frame diameter*

✓ suboptimal placement of the prosthesis

*Skirt position vs sealing zone*

✓ annulus-prosthesis-size mismatch

*Nominal = effective valve diameter*

*Native leaflets vs frame alignment*

( 23mm CoreValve / 21 mm annulus)

# How to manage significant residual aortic regurgitation

## Identification of the mechanism of PAR ?



- ✓ stent frame underexpansion  
*nominal << effective frame diameter*
- ✓ suboptimal placement of the prosthesis  
*Skirt position vs sealing zone*
- ✓ annulus-prosthesis-size mismatch  
*Nominal = effective valve diameter*  
*Native leaflets vs frame alignment*


( 29mm CoreValve / 24 mm annulus)

# How to manage significant residual aortic regurgitation


Identification of the mechanism of PAR ?

**suboptimal placement of the prosthesis**

*Skirt position vs Sealing zone*



( ST 35/ annulus 26)



( ST 24/ annulus 26)

CoreValve 29 mm  
Position 4 mm


— Valve Commissures  
pathways

# How to manage significant residual aortic regurgitation


Identification of the mechanism of PAR ?

**suboptimal placement of the prosthesis**

*Skirt position vs sealing zone*



( ST 35/ annulus 26)



( ST 24/ annulus 26)

CoreValve 29 mm  
Position 4 mm

— Corevalve skirt


*Outflow 29 mm  
Inflow 24 mm*

# How to manage significant residual aortic regurgitation


Identification of the mechanism of PAR ?

**suboptimal placement of the prosthesis**

*Skirt position vs sealing zone*



( ST 35/ annulus 26)



( ST 24/ annulus 26)

CoreValve 29 mm  
Position 4 mm

— Corevalve skirt



*Outflow 29 mm  
Inflow 24 mm*

# How to manage significant residual aortic regurgitation

Identification of the mechanism of PAR ?

**suboptimal placement of the prosthesis**

*Skirt position vs sealing zone*



CoreValve 29 mm  
Position 4 mm

Effective  
sealing zone

# How to manage significant residual aortic regurgitation

Correctives measures ?

- ✓ **Balloon Aortique Valvuloplasty (BAV)**
- ✓ **Valve-in-Valve (ViV)**
- ✓ 2nd valve
- ✓ Valve Repositioning
- ✓ transcatheter device closure procedures
- ✓ Surgery

# How to manage significant residual aortic regurgitation

Correctives mesures of PAR ?

✓ stent frame underexpansion



## Balloon Aortic Valvuloplasty (BAV)

Balloon Size :

- 1<sup>st</sup> choice : Annulus measurement
  - Valve anatomy ( Heavily vs mild Ca+ )
  - Route anatomy ( coronary ostias)
  - Valve position ( High vs Low)
- Max. : 22mm for 23mm CoreValve
- 25mm for 26mm CoreValve
- 28mm for 29 & 31mm CoreValve

Rapid-Pacing

# How to manage significant residual aortic regurgitation

Correctives mesures of PAR ?

✓ stent frame underexpansion ( 31mm Corevalve)




( annulus : Mild Ca+ / 27.5 mm

Balloon size : 28 mm in diameter)

# How to manage significant residual aortic regurgitation

Correctives mesures of PAR ?

- ✓ suboptimal placement of the prosthesis



## Valve-in-Valve (ViV)

Valve Size :

1<sup>st</sup> choice : Same valve size

Valve anatomy ( Coronary ostias, Mitral )

Position for the 2nd valve : original target

# How to manage significant residual aortic regurgitation

Correctives mesures of PAR ?

✓ suboptimal placement of the prosthesis



( annulus : Mild Ca+ / 27.5 mm


Balloon size : 28 mm in diameter)

# How to manage significant residual aortic regurgitation

Correctives mesures of PAR ?

- ✓ suboptimal placement of the prosthesis

**Valve repositioning ( Goose-neck catheter)**



Valve anatomy ( Ca+, Coronary ostias)

Route anatomy

Ascending aorta, Mitral impairment


Reposition for the 2nd valve :

Dictate by hemodynamic measurements

# How to manage significant residual aortic regurgitation

Correctives mesures of PAR ?

✓ suboptimal placement of the prosthesis



# How to manage significant residual aortic regurgitation

Correctives mesures of PAR ?

✓ annulus-prosthesis-size mismatch



**2rd valve**

Valve Size :  
Higher valve size



Valve anatomy ( Ascending aorta)

Position for the 2rd valve : original target

# How to manage significant residual aortic regurgitation

Correctives mesures of PAR ?

✓ annulus-prosthesis-size mismatch (1st valve: 26 mm Corevalve)



( annulus : Mild Ca+ / ~~23~~ 24.5 mm      2rd valve: 29 mm Corevalve)

# How to manage significant residual aortic regurgitation


Correctives mesures of PAR ?

✓ annulus-prosthesis-size mismatch

transcatheter device closure procedures

Device:  
Amplatzer

True PAR vs ruptured sinus of valsalva  
Valve vs Route anatomy position  
( skirt , LVOT)



# Summary

Selection of the proper strategy and potential corrective measure require :

- Accurate assessment of PAR and understanding of his mechanism
- Good assessment of the expected benefit and the potential risk for each optional corrective technique

**THANK YOU**

# Paravalvular Leak: Severity Assessment and Treatment

## Paravalvular Leak

**Transcatheter Aortic Valve Implantation With the Edwards SAPIEN Versus the Medtronic CoreValve Revalving System Devices: A Multicenter Collaborative Study: The PRAGMATIC Plus Initiative**

793 patients were included: 453 (57.1%) treated with the MCV and 340 (42.9%) with the ESV.

